The deal, announced last week, gives Prothena $60 million in upfront cash and potentially up to $1.17 billion tied to achieving development, commercialization and net sales-based milestones, starting with $40 million if the anti-amyloid immunotherapy advances to Phase II . . .

Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR Amyloidosis Candidate to Novo Nordisk
Buyer further builds cardiovascular pipeline with purchase of PRX004
Novo Nordisk has agreed to acquire the ATTR candidate PRX004 from Prothena for up to $1.2 billion. Novo was among companies that expressed to Prothena their interest in developing the humanized monoclonal antibody. [Novo Nordisk]